JP2003528139A - 炎症性サイトカインおよびケモカインの発現を阻害する方法 - Google Patents
炎症性サイトカインおよびケモカインの発現を阻害する方法Info
- Publication number
- JP2003528139A JP2003528139A JP2001570257A JP2001570257A JP2003528139A JP 2003528139 A JP2003528139 A JP 2003528139A JP 2001570257 A JP2001570257 A JP 2001570257A JP 2001570257 A JP2001570257 A JP 2001570257A JP 2003528139 A JP2003528139 A JP 2003528139A
- Authority
- JP
- Japan
- Prior art keywords
- astaxanthin
- expression
- chemokines
- xanthophyll
- inflammatory cytokines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 22
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 20
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 20
- 230000002757 inflammatory effect Effects 0.000 title claims abstract description 20
- 102000019034 Chemokines Human genes 0.000 title claims abstract description 19
- 108010012236 Chemokines Proteins 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims abstract description 14
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 7
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 45
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 45
- 239000001168 astaxanthin Substances 0.000 claims abstract description 45
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 45
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 45
- 235000008210 xanthophylls Nutrition 0.000 claims abstract description 20
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 19
- 229960005375 lutein Drugs 0.000 claims abstract description 19
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 19
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 19
- 241001465754 Metazoa Species 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 10
- 241000282412 Homo Species 0.000 claims abstract description 9
- 230000005764 inhibitory process Effects 0.000 claims abstract description 7
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 7
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 238000013500 data storage Methods 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 7
- 241000195493 Cryptophyta Species 0.000 claims description 6
- 241000168525 Haematococcus Species 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 235000006708 antioxidants Nutrition 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- -1 astaxanthin Chemical compound 0.000 abstract 2
- 102000003945 NF-kappa B Human genes 0.000 description 22
- 108010057466 NF-kappa B Proteins 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 15
- 108700008625 Reporter Genes Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 2
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 2
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102100035100 Transcription factor p65 Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000006697 redox regulation Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 102100023059 Nuclear factor NF-kappa-B p100 subunit Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000005747 Transcription Factor RelA Human genes 0.000 description 1
- 108010031154 Transcription Factor RelA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000010057 immune-inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0001071A SE0001071D0 (sv) | 2000-03-27 | 2000-03-27 | Method of inhibiting the expression of inflammatory cytokines and chemokines |
| SE0001071-0 | 2000-03-27 | ||
| PCT/SE2001/000600 WO2001072296A1 (en) | 2000-03-27 | 2001-03-21 | Method of inhibiting the expression of inflammatory cytokines and chemokines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528139A true JP2003528139A (ja) | 2003-09-24 |
| JP2003528139A5 JP2003528139A5 (enExample) | 2008-05-15 |
Family
ID=20279020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001570257A Pending JP2003528139A (ja) | 2000-03-27 | 2001-03-21 | 炎症性サイトカインおよびケモカインの発現を阻害する方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1267857B1 (enExample) |
| JP (1) | JP2003528139A (enExample) |
| AT (1) | ATE353639T1 (enExample) |
| AU (1) | AU2001242965A1 (enExample) |
| CA (1) | CA2405479C (enExample) |
| DE (1) | DE60126591D1 (enExample) |
| SE (1) | SE0001071D0 (enExample) |
| WO (1) | WO2001072296A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005074907A1 (ja) * | 2004-02-04 | 2005-08-18 | Fuji Chemical Industry Co., Ltd. | 遺伝子発現調節剤 |
| JP2006008718A (ja) * | 2005-06-03 | 2006-01-12 | Yamaha Motor Co Ltd | シクロオキシゲナーゼ活性阻害剤 |
| JP2006008719A (ja) * | 2005-06-23 | 2006-01-12 | Yamaha Motor Co Ltd | 血中過酸化脂質抑制剤 |
| JP2006008714A (ja) * | 2005-03-17 | 2006-01-12 | Yamaha Motor Co Ltd | マトリックスメタロプロテイナーゼ阻害剤 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002349784A1 (en) * | 2001-12-03 | 2003-06-17 | Asahi Kasei Pharma Corporation | Nf-kappab activating genes |
| WO2008106606A2 (en) * | 2007-02-28 | 2008-09-04 | Cardax Pharmaceuticals, Inc. | Carotenoid analogs and derivatives in the treatment of prostate cancer |
| US7805004B2 (en) * | 2007-02-28 | 2010-09-28 | Microsoft Corporation | Radical set determination for HMM based east asian character recognition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05155736A (ja) * | 1991-12-10 | 1993-06-22 | Nakano Seiyaku Kk | 化粧料 |
| JPH09143063A (ja) * | 1995-11-22 | 1997-06-03 | Kose Corp | 外用に適する組成物 |
| WO1998037874A1 (en) * | 1997-02-27 | 1998-09-03 | Astacarotene Ab | Oral preparation for the prophylactic and therapeutic treatment of helicobacter sp. infection |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0799924A (ja) * | 1993-09-30 | 1995-04-18 | Nippon Suisan Kaisha Ltd | アスタキサンチンを主要成分とするファフィア色素油の安定な粉末化物及びその製造方法 |
| JPH07300421A (ja) * | 1994-04-28 | 1995-11-14 | Itano Reitou Kk | 抗炎症剤 |
| US5527533A (en) * | 1994-10-27 | 1996-06-18 | Board Of Trustees Of The University Of Illinois | Method of retarding and ameliorating central nervous system and eye damage |
| EP0806946A2 (de) * | 1995-02-03 | 1997-11-19 | Basf Aktiengesellschaft | Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen |
| JPH09124470A (ja) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | 抗ストレス組成物 |
| WO1998045241A2 (en) * | 1997-04-04 | 1998-10-15 | Henkel Corporation | Lutein esters having high bioavailability |
| SE512531C2 (sv) * | 1997-09-04 | 2000-03-27 | Astacarotene Ab | Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur |
-
2000
- 2000-03-27 SE SE0001071A patent/SE0001071D0/xx unknown
-
2001
- 2001-03-21 JP JP2001570257A patent/JP2003528139A/ja active Pending
- 2001-03-21 DE DE60126591T patent/DE60126591D1/de not_active Expired - Fee Related
- 2001-03-21 AU AU2001242965A patent/AU2001242965A1/en not_active Abandoned
- 2001-03-21 AT AT01916022T patent/ATE353639T1/de not_active IP Right Cessation
- 2001-03-21 WO PCT/SE2001/000600 patent/WO2001072296A1/en not_active Ceased
- 2001-03-21 CA CA2405479A patent/CA2405479C/en not_active Expired - Fee Related
- 2001-03-21 EP EP01916022A patent/EP1267857B1/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05155736A (ja) * | 1991-12-10 | 1993-06-22 | Nakano Seiyaku Kk | 化粧料 |
| JPH09143063A (ja) * | 1995-11-22 | 1997-06-03 | Kose Corp | 外用に適する組成物 |
| WO1998037874A1 (en) * | 1997-02-27 | 1998-09-03 | Astacarotene Ab | Oral preparation for the prophylactic and therapeutic treatment of helicobacter sp. infection |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005074907A1 (ja) * | 2004-02-04 | 2005-08-18 | Fuji Chemical Industry Co., Ltd. | 遺伝子発現調節剤 |
| JPWO2005074907A1 (ja) * | 2004-02-04 | 2007-09-13 | 富士化学工業株式会社 | 遺伝子発現調節剤 |
| US10828269B2 (en) | 2004-02-04 | 2020-11-10 | Fuji Chemical Industries Co., Ltd. | Reducing muscle atrophy by administering astaxanthin |
| JP2006008714A (ja) * | 2005-03-17 | 2006-01-12 | Yamaha Motor Co Ltd | マトリックスメタロプロテイナーゼ阻害剤 |
| JP2006008718A (ja) * | 2005-06-03 | 2006-01-12 | Yamaha Motor Co Ltd | シクロオキシゲナーゼ活性阻害剤 |
| JP2006008719A (ja) * | 2005-06-23 | 2006-01-12 | Yamaha Motor Co Ltd | 血中過酸化脂質抑制剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2405479A1 (en) | 2001-10-04 |
| ATE353639T1 (de) | 2007-03-15 |
| DE60126591D1 (de) | 2007-03-29 |
| SE0001071D0 (sv) | 2000-03-27 |
| EP1267857A1 (en) | 2003-01-02 |
| AU2001242965A1 (en) | 2001-10-08 |
| CA2405479C (en) | 2010-11-16 |
| WO2001072296A1 (en) | 2001-10-04 |
| EP1267857B1 (en) | 2007-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Inhibition of HDAC6 attenuates LPS-induced inflammation in macrophages by regulating oxidative stress and suppressing the TLR4-MAPK/NF-κB pathways | |
| Zhong et al. | Energy stress modulation of AMPK/FoxO3 signaling inhibits mitochondria-associated ferroptosis | |
| Xu et al. | 5-(3, 4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1, 2, 4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson's disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress | |
| EP3641819B1 (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| Lee et al. | SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth | |
| CA2292497C (en) | Dietary compositions for enhancing metabolism and alleviating oxidative stress | |
| CN1947717B (zh) | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 | |
| Igawa et al. | N‐(4‐hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells | |
| Gallily et al. | Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid | |
| US20070088078A1 (en) | Methods for managing adipocyte fat accumulation | |
| Wang et al. | A new pharmacological effect of levornidazole: inhibition of NLRP3 inflammasome activation | |
| Liu et al. | Cytochrome P450 enzymes mediated by DNA methylation is involved in deoxynivalenol-induced hepatoxicity in piglets | |
| Zhu et al. | HDAC6 alleviates prion peptide-mediated neuronal death via modulating PI3K-Akt-mTOR pathway | |
| Molina-Salinas et al. | Prolactin-induced neuroprotection against excitotoxicity is mediated via PI3K/AKT and GSK3β/NF-κB in primary cultures of hippocampal neurons | |
| US7078040B2 (en) | Method of inhibiting the expression of inflammatory cytokines and chemokines | |
| AU2017314833A1 (en) | Compositions and methods for promoting hair growth with mpc inhibitors | |
| WO2018039612A1 (en) | Compositions and methods for promoting hair growth with mpc1 inhibitors | |
| Eddahibi et al. | Dexfenfluramine-associated changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats | |
| JP2003528139A (ja) | 炎症性サイトカインおよびケモカインの発現を阻害する方法 | |
| Li et al. | PGC-1α Promotes mitochondrial biosynthesis and energy metabolism of goose fatty liver | |
| Walker | Reactive oxygen species in status epilepticus | |
| He et al. | Transcription factor CDX2 directly regulates the expression of Ctenopharyngodon idellus intestinal PepT1 to mediate the transportation of oligopeptide | |
| EP1501520A1 (en) | Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels | |
| US20110015410A1 (en) | Novel use of scoparone | |
| Weinreich et al. | 1, 25-dihydroxyvitamin D3 and the synthetic vitamin D analogue, KH 1060, modulate the growth of mouse proximal tubular cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080321 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080321 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110624 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110823 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111007 |